Monthly Prescribing Reference5d
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...
ots4d
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neur
The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...
Organon updates outlook as FDA delays VTAMA label expansion
Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...
Organon reports FDA extension of target action date of review of Vtama sNDA
Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...
pressat4d
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA
The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.
Arcutis Biotherapeutics Reports Strong Q3 2024 Results
Arcutis Biotherapeutics Inc ( (ARQT) ) has released its Q3 earnings. Here is a breakdown of the information Arcutis Biotherapeutics Inc ...
manilatimes6d
FibroGen to Report Third Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM ...
Future Market Insights3d
Galactoarabinan Market Poised for Growth, Driven by Increasing Applications in Cosmetics, Food, and Pharmaceutical Industries
Asia-Pacific – The Asia-Pacific region is projected to experience the highest growth in the galactoarabinan market, primarily ...